Dr. Reddy's Laboratories Limited (RDY) Income Statement Analysis

See more : Haoersai Technology Group Corp., Ltd. (002963.SZ) Income Statement Analysis – Financial Results

Complete financial analysis of Dr. Reddy’s Laboratories Limited (RDY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dr. Reddy’s Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T) Income Statement Analysis – Financial Results
Gandhar Oil Refinery (India) Limited (GANDHAR.BO) Income Statement Analysis – Financial Results
Investimentos Bemge S.A. (FIGE3.SA) Income Statement Analysis – Financial Results
Jenburkt Pharmaceuticals Limited (JENBURPH.BO) Income Statement Analysis – Financial Results
Lithium Universe Limited (LU7.AX) Income Statement Analysis – Financial Results

Dr. Reddy's Laboratories Limited (RDY)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.drreddys.com

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Revenue	279.16B	245.88B	214.39B	189.72B	174.60B	153.85B	142.03B	140.81B	154.71B	148.19B	132.17B	116.27B	96.74B	74.69B	70.28B	69.44B	50.01B	65.25B	24.33B	19.47B	20.12B	18.02B	16.60B	10.94B
Cost of Revenue	115.56B	42.91B	100.55B	86.65B	80.59B	70.42B	65.72B	62.45B	62.43B	62.79B	56.37B	55.69B	43.43B	34.43B	33.94B	32.94B	24.60B	34.30B	12.45B	9.39B	9.37B	7.82B	6.86B	5.72B
Gross Profit	163.61B	202.97B	113.84B	103.08B	94.01B	83.43B	76.30B	78.36B	92.28B	85.40B	75.80B	60.58B	53.31B	40.26B	36.34B	36.50B	25.41B	30.95B	11.88B	10.09B	10.76B	10.20B	9.74B	5.22B
Gross Profit Ratio	58.61%	82.55%	53.10%	54.33%	53.84%	54.23%	53.72%	55.65%	59.65%	57.63%	57.35%	52.10%	55.10%	53.90%	51.71%	52.56%	50.81%	47.43%	48.83%	51.80%	53.46%	56.62%	58.68%	47.74%
Research & Development	22.87B	19.38B	17.48B	16.54B	15.41B	15.61B	18.27B	19.55B	17.83B	17.45B	12.40B	7.67B	5.91B	5.06B	3.79B	4.04B	3.53B	2.47B	2.16B	2.80B	2.00B	1.37B	740.85M	506.99M
General & Administrative	0.00	46.47B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	59.47B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	77.20B	105.93B	62.08B	54.56B	50.13B	48.89B	46.91B	46.37B	45.70B	42.59B	38.78B	33.58B	28.87B	23.69B	22.51B	21.02B	15.18B	14.08B	8.05B	6.81B	6.58B	5.01B	3.66B	2.81B
Other Expenses	-4.20B	-7.70B	-2.76B	-982.00M	-4.29B	-691.00M	-843.00M	-1.15B	-986.00M	-1.06B	-1.36B	-2.34B	-784.00M	-1.12B	-569.00M	254.00M	3.34B	3.14B	226.45M	838.82M	100.65M	488.15M	278.38M	418.71M
Operating Expenses	95.88B	117.62B	76.80B	70.12B	61.25B	62.54B	64.39B	64.86B	62.66B	59.12B	49.77B	38.78B	34.01B	27.64B	25.73B	25.31B	22.05B	19.70B	10.43B	10.45B	8.67B	6.86B	4.68B	3.73B
Cost & Expenses	211.44B	160.52B	177.35B	156.76B	141.84B	132.96B	130.11B	127.31B	125.09B	121.90B	106.14B	94.47B	77.45B	62.07B	59.67B	58.25B	46.65B	54.00B	22.88B	19.84B	18.04B	14.68B	11.54B	9.45B
Interest Income	2.28B	1.18B	3.08B	2.62B	888.00M	2.28B	540.00M	558.00M	1.40B	1.06B	1.09B	900.00M	377.00M	173.00M	369.00M	482.00M	1.60B	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	1.71B	1.43B	958.00M	970.00M	983.00M	1.16B	788.00M	634.00M	826.00M	1.09B	1.27B	1.02B	1.07B	362.00M	372.00M	1.67B	1.08B	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	14.84B	12.64B	11.82B	12.80B	12.47B	12.19B	11.71B	11.28B	10.25B	8.10B	7.11B	5.55B	5.21B	4.15B	4.16B	3.81B	6.20B	3.02B	1.57B	1.31B	1.13B	1.01B	945.26M	892.60M
EBITDA	88.42B	74.43B	47.74B	45.71B	41.79B	31.87B	23.74B	24.55B	40.18B	35.16B	33.14B	22.49B	20.33B	16.82B	6.59B	1.49B	7.31B	14.27B	2.71B	1.02B	2.83B	4.35B	6.01B	2.38B
EBITDA Ratio	31.67%	44.24%	24.55%	25.75%	28.37%	15.34%	8.39%	9.59%	19.15%	17.74%	19.70%	19.34%	21.02%	16.90%	21.61%	22.33%	16.79%	23.67%	11.13%	4.24%	14.09%	22.62%	33.95%	21.17%
Operating Income	67.73B	96.28B	40.82B	36.06B	37.06B	20.89B	11.92B	13.50B	29.62B	26.29B	26.03B	21.11B	18.25B	12.63B	2.01B	-2.83B	3.36B	11.25B	1.45B	-366.46M	2.08B	3.34B	5.06B	1.49B
Operating Income Ratio	24.26%	39.16%	19.04%	19.01%	21.22%	13.58%	8.39%	9.59%	19.15%	17.74%	19.70%	18.16%	18.87%	16.91%	2.86%	-4.08%	6.71%	17.24%	5.94%	-1.88%	10.36%	18.52%	30.47%	13.59%
Total Other Income/Expenses	4.14B	3.34B	2.82B	4.04B	2.04B	1.56B	2.42B	1.16B	-2.48B	1.88B	574.00M	1.41B	214.00M	-186.00M	-7.99B	-15.44B	-493.72M	-725.88M	446.53M	107.40M	465.35M	572.90M	9.11M	-426.12M
Income Before Tax	71.87B	60.49B	32.30B	28.32B	18.03B	22.44B	14.34B	14.65B	27.14B	28.16B	26.61B	21.68B	18.47B	12.44B	2.05B	-4.00B	3.44B	10.53B	1.89B	107.03M	2.55B	3.92B	5.07B	1.06B
Income Before Tax Ratio	25.74%	24.60%	15.06%	14.93%	10.33%	14.59%	10.10%	10.41%	17.54%	19.00%	20.13%	18.64%	19.09%	16.66%	2.92%	-5.75%	6.88%	16.13%	7.78%	0.55%	12.65%	21.75%	30.53%	9.69%
Income Tax Expense	16.19B	15.41B	8.73B	9.18B	-1.47B	3.65B	4.54B	2.61B	7.13B	5.98B	5.09B	4.90B	4.20B	1.40B	985.00M	1.17B	-1.23B	1.18B	259.07M	-94.28M	69.41M	396.92M	153.68M	320.24M
Net Income	55.68B	45.07B	23.57B	17.24B	19.50B	18.80B	9.81B	12.04B	20.01B	22.18B	21.51B	16.78B	14.26B	11.04B	1.07B	-5.17B	4.68B	9.35B	1.63B	211.27M	2.48B	3.52B	4.92B	739.28M
Net Income Ratio	19.95%	18.33%	10.99%	9.09%	11.17%	12.22%	6.90%	8.55%	12.94%	14.97%	16.28%	14.43%	14.74%	14.78%	1.52%	-7.44%	9.36%	14.33%	6.71%	1.08%	12.32%	19.55%	29.60%	6.76%
EPS	334.02	271.47	142.08	103.94	117.62	113.28	59.13	72.24	117.34	130.22	126.52	98.82	84.16	65.28	6.33	-30.70	22.88	58.46	10.64	1.38	15.79	23.05	32.33	5.85
EPS Diluted	334.02	270.90	141.69	103.65	117.40	113.09	59.01	72.09	116.98	129.75	126.04	98.44	83.81	64.95	6.30	-30.70	22.80	58.21	10.62	1.38	15.78	23.05	32.27	5.85
Weighted Avg Shares Out	166.71M	166.03M	165.88M	165.84M	165.76M	165.92M	165.85M	166.65M	170.55M	170.31M	170.04M	169.78M	169.47M	169.13M	168.71M	168.35M	168.08M	158.55M	153.09M	153.04M	153.03M	153.03M	152.06M	126.36M
Weighted Avg Shares Out (Dil)	166.71M	166.38M	166.34M	166.32M	166.08M	166.20M	166.19M	167.00M	171.07M	170.93M	170.70M	170.43M	170.18M	169.97M	169.62M	168.35M	168.69M	159.26M	153.40M	153.12M	153.10M	153.03M	152.30M	126.36M

Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

May 22, 2024zacks.com

Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 21, 2024businesswire.com

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva®.

Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term

May 9, 2024zacks.com

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow

May 8, 2024zacks.com

Dr. Reddy's (RDY) posts better-than-expected fiscal fourth-quarter results on growth in global generics revenues in North America as well as Emerging Markets.

Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript

May 7, 2024seekingalpha.com

Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q4 2024 Earnings Conference Call May 7, 2024 10:00 AM ET Company Participants Richa Periwal - Head of Investor Relations GV Prasad - Co-Chairman and Managing Director Parag Agarwal - Chief Financial Officer Erez...